Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute thunderclap headache, evidence of vasoconstriction in conventional angiography or magnetic resonance angiography and reversibility of these phenomena within 12 weeks. Some triggering factors, for example drugs such as selective serotonin reuptake inhibitors, sumatriptan, tacrolimus, cyclophosphamide and cocaine, or states such as pregnancy, puerperium or migraine have been described. We describe the case of a 29-year-old woman with RCVS associated with fingolimod three months after childbirth. This case represents the first report of RCVS in fingolimod treatment.
Department of Neurology, Alfried Krupp Hospital, Essen, Germany markus.kraemer@krupp-krankenhaus.de.
Markus
M
Kraemer
Department of Neurology, Alfried Krupp Hospital, Essen, Germany.
Ralph
R
Weber
Department of Neurology, Alfried Krupp Hospital, Essen, Germany.
Michèle
M
Herold
Department of Neurology, Alfried Krupp Hospital, Essen, Germany.
Peter
P
Berlit
D000328:Adult; D002561:Cerebrovascular Disorders / Q000139:chemically induced*; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D036801:Parturition; D011247:Pregnancy; D013577:Syndrome; D014661:Vasoconstriction / Q000187:drug effects*
D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride
Reversible cerebral vasoconstriction syndrome; fingolimod; trigger